Screening Drugs for Kidney Disease: Targeting the Podocyte

Joshua S Bryer; Katalin Susztak

doi:10.1016/j.chembiol.2018.01.018

Screening Drugs for Kidney Disease: Targeting the Podocyte

Cell Chem Biol. 2018 Feb 15;25(2):126-127. doi: 10.1016/j.chembiol.2018.01.018.

Authors

Joshua S Bryer¹, Katalin Susztak²

Affiliations

¹ Renal-Electrolyte and Hypertension Division of Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
² Renal-Electrolyte and Hypertension Division of Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: ksusztak@pennmedicine.upenn.edu.

PMID: 29452609
DOI: 10.1016/j.chembiol.2018.01.018

Abstract

Podocytes cover the kidney glomerular basement membrane and present the final barrier in the renal filtration system. Podocyte loss, observed in most kidney diseases, correlates with kidney function decline. In this issue of Cell Chemical Biology, Seiber et al. (2018), using a high-throughput chemical screen, identified the compound CDG-0876, which improved podocyte survival.

Publication types

Research Support, N.I.H., Extramural
Comment

MeSH terms

Humans
Indenes
Kidney Diseases*
Podocytes*
Proto-Oncogene Proteins B-raf
Pyrazoles

Substances

2-(4-(1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl)-3-(pyridin-4-yl)-1H-pyrazol-1-yl)ethan-1-ol
Indenes
Pyrazoles
BRAF protein, human
Proto-Oncogene Proteins B-raf